Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Directorate Change

29 May 2013 07:00

RNS Number : 7347F
Silence Therapeutics PLC
29 May 2013
 



 

Appointment of chief executive and director of corporate development

29th May 2013

Silence Therapeutics plc (AIM: SLN) announces today the appointment of Ali Mortazavi as chief executive and of Annie Cheng as director of corporate development.

Ali Mortazavi joined Silence in August 2012 as director of corporate strategy and since that time has increasingly taken on the mantle of the CEO role. This included overseeing two fundraisings last year to raise £11m for the company and spearheading the £19m placing completed in April 2013. Ali has over 17 years of experience in financial services. He started his career as a Technology Analyst at Duncan Lawrie then Credit Lyonnais Securities. In 2001, he co-founded Evolution Securities and ran the principal trading and market making arm, leaving in 2008. He has extensive experience in small companies and has had significant stakes in UK listed technology / biotech ventures.

Annie Cheng (Annie Jia Huey Cheng), age 37, joins the company after working as a strategy consultant for the Company since October 2012. She has 14 years of experience in the healthcare industry, in equity research and consulting with JP Morgan and boutique investment banks in New York and London.

She has been a director of Visible Value LLP, a biotech consultancy, since December 2011 and of Valor Visible Ltd, its associated business, since October 2012.

There are no other matters to disclose regarding her appointment under Rule 17 or Schedule 2 paragraph (g) of the AIM Rules for Companies.

 

Chairman Jerry Randall said: 'Ali brings a wealth of experience in the capital markets as well as small cap companies, and has been instrumental in the development of Silence since he joined. Annie's combination of investor and commercial experience is very valuable.'

 

Silence Therapeutics

Ali Mortazavi, chief executive/Timothy Freeborn, finance director +44 (0)333 988 0140

a.mortazavi@silence-therapeutics.com

t.freeborn@silence-therapeutics.com

 

N+1 Singer

Shaun Dobson/Jenny Wyllie

+44 20 7496 3000

shaun.dobson@n1singer.com

jenny.wyllie@n1singer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGUBPAUPWGQR
Date   Source Headline
20th Jan 20203:23 pmRNSHolding(s) in Company
13th Jan 20208:37 amRNSHolding(s) in Company
9th Jan 202010:04 amEQSEdison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)
9th Jan 20208:43 amRNSHolding(s) in Company
8th Jan 20209:11 amRNSHolding(s) in Company
7th Jan 202010:12 amRNSHolding(s) in Company
7th Jan 20207:00 amRNSSilence Therapeutics Announces Business Update
27th Dec 20197:00 amRNSHolding(s) in Company
17th Dec 20193:31 pmRNSManagement Change
17th Dec 20197:45 amRNSDirector disclosure
17th Dec 20197:45 amRNSBoard changes
27th Nov 20199:14 amRNSAdditional Listing
22nd Nov 20199:23 amRNSAdditional Listing
13th Nov 20192:45 pmRNSHolding(s) in Company
30th Oct 20193:13 pmRNSAdditional Listing
25th Oct 201910:25 amRNSAdditional Listing
14th Oct 201910:40 amRNSHolding(s) in Company
7th Oct 20197:00 amRNSHoldings in Company
7th Oct 20197:00 amRNSGrant of share options
4th Oct 20195:21 pmRNSDirector/PDMR Shareholding and Additional Listing
3rd Oct 20193:40 pmRNSDirector/PDMR Shareholding
2nd Oct 20195:09 pmRNSDirector/PDMR Shareholding
1st Oct 20196:06 pmRNSDirector/PDMR Shareholding and Additional Listing
30th Sep 20195:09 pmRNSDirector/PDMR Shareholding
24th Sep 20197:00 amRNSFirst research milestone for SLN500
20th Sep 20193:19 pmRNSAdditional Listing
16th Sep 20194:46 pmRNSAdditional Listing
12th Sep 20197:00 amRNSInterim results for six months ended 30 June 2019
27th Aug 20198:28 amRNSHolding(s) in Company
21st Aug 201910:14 amRNSAdditional Listing
19th Aug 20193:15 pmRNSAdditional Listing
15th Aug 20197:00 amRNSNotice of Results and R&D day
13th Aug 20197:00 amRNSAdditional Listing
8th Aug 20194:27 pmRNSAdditional Listing
7th Aug 20191:38 pmRNSAdditional Listing
6th Aug 201912:41 pmRNSAdditional Listing
5th Aug 20197:00 amRNSSilence Therapeutics appoints Jørgen Wittendorff
1st Aug 20194:22 pmRNSHolding(s) in Company
31st Jul 20198:19 amRNSHolding(s) in Company
30th Jul 20195:30 pmRNSAdditional Listing
29th Jul 20197:00 amRNSBoard Appointment
26th Jul 20191:33 pmRNSHolding(s) in Company
25th Jul 201912:26 pmRNSHolding(s) in Company
24th Jul 20198:43 amRNSHolding(s) in Company
23rd Jul 201911:27 amRNSAdditional Listing
19th Jul 20194:35 pmRNSPrice Monitoring Extension
19th Jul 20193:13 pmRNSAdditional Listing
18th Jul 201911:46 amRNSMallinckrodt to make equity investment in Silence
18th Jul 201911:45 amRNSSilence collaboration with Mallinckrodt
16th Jul 201911:46 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.